Midgard Science

Tobiopharm

Nantong, China tobiopharm.com From their website, Nov 2026

Work here? Claim this listing

About

Aoscang Biopharma (Nantong) Co., Ltd. was founded in 2011, is headquartered in Nantong, Jiangsu, and provides early-stage R&D, cell culture media, and biopharmaceutical contract development and manufacturing services. The company has business and manufacturing operations in Jiangsu and Shanghai in China, Gansu, as well as South Korea and the United States, providing integrated solutions for biopharmaceutical R&D and commercial manufacturing customers.

Services

  • AI prediction and development platform

    Provides AI prediction and development support for multiple molecules, covering capabilities related to high-expression cell line development.

  • Antibody discovery and engineering modification platform

    Provides services related to antibody discovery, optimization, and engineering modification.

  • Novel linker-toxin and conjugation platform

    Provides development services related to linker and toxin screening and conjugation.

  • Pharmacology, efficacy, and pharmacokinetics evaluation platform

    Provides pharmacology, efficacy, and pharmacokinetics evaluation services.

  • Druggability evaluation platform

    Provides molecular druggability evaluation services.

  • Early-stage sample preparation and cell line construction platform

    Provides early-stage R&D sample preparation and cell line construction services.

  • Structural characterization and novel formulation development platform

    Provides structure-function characterization and novel formulation development services.

  • Innovative complex molecule design and development platform

    Provides design and development services for complex molecules.

11 more services
  • Commercial culture media
  • Culture media formulation contract manufacturing
  • Recombinant protein drug production
  • Antibody production
  • ADC production
  • Upstream production
  • Downstream purification
  • Formulation production
  • Process development
  • Analysis and formulation
  • Culture media development

Capabilities

Assays and studies
  • ADCs
  • Target design
  • Molecule optimization
  • Molecule evaluation
  • Antibody discovery
  • Engineering modification
6 more
  • Druggability evaluation
  • Pharmacology and efficacy evaluation
  • Pharmacokinetics evaluation
  • Structural characterization
  • Physicochemical and biochemical characterization
  • Analytical testing
Scale and capacity
  • CDMO base of over 40,000 square meters
  • Nantong macromolecule drug industrialization base: 5 traditional drug substance production lines
  • 1 perfusion process production line
  • Vial liquid injection/lyophilized formulation production line, 100,000 bottles per batch
  • Pre-filled syringe formulation production line, 64,000 syringes per batch
  • Shanghai ADC production center, ADC formulation capacity of 120,000 bottles per batch
7 more
  • Gansu Lanzhou base with a total area of 9,908 square meters
  • Jiangsu Nantong culture media industrialization base, 6 tons of dry powder per batch
  • South Korea Busan culture media base with a total area of 16,827 square meters
  • 5000L bioreactor annual demand
  • 年产能超千万升
  • 100kg, 200kg, 400kg-grade production lines
  • 50kg, 850kg, 6,000kg-grade production lines
Therapeutic areas
  • Biopharmaceuticals
  • Antibody drugs
  • Antibody-drug conjugates (ADC)
  • Recombinant proteins
  • Human and veterinary vaccines
  • Cell therapy

Instruments and platforms

  • 200L single-use bioreactor
  • 500L single-use bioreactor
  • 2000L single-use bioreactor
  • Isolator filling line
  • Traditional conjugation system
  • Enzymatic conjugation system
3 more
  • Single-use conjugation technology
  • Fully automatic cone mixer
  • Low-temperature pin mill

Modalities and species

Modalities
ADC
Species and models
哺乳动物细胞表达系统

Certifications

As the company states them, with the certificate or registry record where there is one.

  • GMPSelf-reported

    Scope: 培养基生产基地

Company

Type
CRDMO
Founded
2011
Quality
中国GMP (Nantong macromolecule drug industrialization base) · FDA (Nantong macromolecule drug industrialization base) · EMA (Nantong macromolecule drug industrialization base) · OEB-5级标准 (Shanghai ADC R&D and GMP production base) · cGMP (Culture media production base)

Locations

Based in
Nantong, China
Sites
  • 南通, 中国
  • 上海, 中国
  • 兰州, 中国
  • 釜山, 韩国
  • Pleasanton, 美国
Serves
China, South Korea, United States, Asia-Pacific region, European and American customers, Global

Similar labs